Cinepazide maleate improves cognitive function and protects hippocampal neurons in diabetic rats with chronic cerebral hypoperfusion

Biological and Pharmaceutical Bulletin

Volumn 40, Issue 3, 2017, Pages 249-255

  Li, Yumei ^a,b   Zhang, Ting ^a   Zhang, Xiaojie ^a   Zou, Wenying ^a   Gong, Xian ^b   Fu, Jianliang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Third Hospital of Nanchang   (China)

Author keywords

Chronic cerebral hypoperfusion; Cinepazide maleate; Cognitive impairment; Diabetes

Indexed keywords

BETA SECRETASE 1; CHOLINE ACETYLTRANSFERASE; CINEPAZIDE MALEATE; GLIAL FIBRILLARY ACIDIC PROTEIN; STREPTOZOCIN; UNCLASSIFIED DRUG; VASODILATOR AGENT; ASPARTIC PROTEINASE; BACE PROTEIN, RAT; CINEPAZIDE; NEUROPROTECTIVE AGENT; PIPERAZINE DERIVATIVE; SECRETASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; BRAIN DAMAGE; CAROTID ARTERY; CHRONIC DISEASE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; HIPPOCAMPUS; LEARNING; LIPID DIET; MALE; MORRIS WATER MAZE TEST; NERVE CELL; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPATIAL MEMORY; ANIMAL; BRAIN; BRAIN ISCHEMIA; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; MAZE TEST; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; SPRAGUE DAWLEY RAT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; BRAIN ISCHEMIA; CHOLINE O-ACETYLTRANSFERASE; COGNITION; COGNITION DISORDERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; LEARNING; MALE; MAZE LEARNING; NEURONS; NEUROPROTECTIVE AGENTS; PIPERAZINES; RATS, SPRAGUE-DAWLEY; SPATIAL MEMORY; VASODILATOR AGENTS;

EID: 85014348193     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b16-00567     Document Type: Article

References (38)

1. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann. N. Y. Acad. Sci., 977, 196-215 (2002).
2. Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res. Rev., 54, 162-180 (2007).
3. Humpel C, Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease. Curr. Neurovasc. Res., 2, 341-347 (2005).
4. Ohta H, Nishikawa H, Kimura H, Anayama H, Miyamoto M. Chronic cerebral hypoperfusion by permanent internal carotid ligation produces learning impairment without brain damage in rats. Neuroscience, 79, 1039-1050 (1997).
5. Komatani A, Yamaguchi K, Sugai Y, Takanashi T, Kera M, Shinohara M, Kawakatsu S. Assessment of demented patients by dynamic SPECT of inhaled xenon-133. J. Nucl. Med., 29, 1621-1626 (1988).
6. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer's disease. Diabetes, 53, 474-481 (2004).
7. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol., 64, 575-611 (2001).
8. Ni J, Ohta H, Matsumoto K, Watanabe H. Progressive cognitive impairment following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries in rats. Brain Res., 653, 231-236 (1994).
9. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A. Long-term measurements of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin. Exp. Pharmacol. Physiol., 30, 266-272 (2003).
10. Pappas BA, De la Torre JC, Davidson CM, Keyes MT, Fortin T. Chronic reduction of cerebral blood flow in the adult rat: lateemerging CA1 cell loss and memory dysfunction. Brain Res., 708, 50-58 (1996).
11. Sarti C, Pantoni L, Bartolini L, Inzitari D. Cognitive impairment and chronic cerebral hypoperfusion: what can be learned from experimental models. J. Neurol. Sci., 203-204, 263-266 (2002).
12. Bennett SA, Tenniswood M, Chen JH, Davidson CM, Keyes MT, Fortin T, Pappas BA. Chronic cerebral hypoperfusion elicits neuronal apoptosis and behavioral impairment. Neuroreport, 9, 161-166 (1998).
13. Zhang T, Pan BS, Zhao B, Zhang LM, Huang YL, Sun FY. Exacerbation of poststroke dementia by type 2 diabetes is associated with synergistic increases of beta-secretase activation and beta-amyloid generation in rat brains. Neuroscience, 161, 1045-1056 (2009).
14. Cechetti F, Pagnussat AS, Worm PV, Elsner VR, Ben J, da Costa MS, Mestriner R, Weis SN, Netto CA. Chronic brain hypoperfusion causes early glial activation and neuronal death, and subsequent long-term memory impairment. Brain Res. Bull., 87, 109-116 (2012).
15. Hirohashi M, Hagihara Y. Effect of 1-((1-pyrrolidynylcarbonyl)-methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine maleate (cinepazide) on cerebral and peripheral circulation in cats. (author's transl.). Nippon Yakurigaku Zasshi, 75, 495-506 (1979).
16. Moritoki H, Takei M, Fujita S, Ishida Y, Akashi A. Interaction of cinepazide with adenosine on guinea-pig atria. Arch. Int. Pharmacodyn. Ther., 248, 212-224 (1980).
17. Zhu Y, Zhang G, Zhao J, Li D, Yan X, Liu J, Liu X, Zhao H, Xia J, Zhang X, Li Z, Zhang B, Guo Z, Feng L, Zhang Z, Qu F, Zhao G. Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. Clin. Drug Investig., 33, 755-760 (2013).
18. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat. Protoc., 1, 848-858 (2006).
19. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res., 52, 313-320 (2005).
20. Reisi P, Alaei H, Babri S, Sharifi MR, Mohaddes G. Effects of treadmill running on spatial learning and memory in streptozotocin-induced diabetic rats. Neurosci. Lett., 455, 79-83 (2009).
21. Hellweg R, Nitsch R, Hock C, Jaksch M, Hoyer S. Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism. J. Neurosci. Res., 31, 479-486 (1992).
22. Blokland A, Jolles J. Spatial learning deficit and reduced hippocampal ChAT activity in rats after an ICV injection of streptozotocin. Pharmacol. Biochem. Behav., 44, 491-494 (1993).
23. Prickaerts J, Fahrig T, Blokland A. Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Behav. Brain Res., 102, 73-88 (1999).
24. Duffy PE, Rapport M, Graf L. Glial fibrillary acidic protein and Alzheimer-type senile dementia. Neurology, 30, 778-782 (1980).
25. Albrink MJ. Dietary and drug treatment of hyperlipidemia in diabetes. Diabetes, 23, 913-918 (1974).
26. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP - thirty-one years (1969-2000). Neurochem. Res., 25, 1439-1451 (2000).
27. O'Callaghan JP, Sriram K. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin. Drug Saf., 4, 433-442 (2005).
28. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol., 18, 315-321 (2005).
29. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol., 51, 145-155 (2002).
30. Fraser DD, MacVicar BA. Cholinergic-dependent plateau potential in hippocampal CA1 pyramidal neurons. J. Neurosci., 16, 4113-4128 (1996).
31. Musilli M, Nicolia V, Borrelli S, Scarpa S, Diana G. Behavioral effects of Rho GTPase modulation in a model of Alzheimer's disease. Behav. Brain Res., 237, 223-229 (2013).
32. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science, 215, 1237-1239 (1982).
33. Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J. Neural Transm., 111, 523-536 (2004).
34. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res., 1009, 1-8 (2004).
35. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen M, Yang SH, Zhong Z, Shen Y, Simpkins JW, Tanzi RE. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron, 54, 721-737 (2007).
36. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A., 101, 3632-3637 (2004).
37. Harada H, Tamaoka A, Ishii K, Shoji S, Kametaka S, Kametani F, Saito Y, Murayama S. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci. Res., 54, 24-29 (2006).
38. Chen Y, Huang XM, Zhang YW, Rockenstein E, Bu G, Golde TE, Masliah E, Xu H. Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. J. Neurosci., 32, 11390-11395 (2012).